GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Price-to-Tangible-Book

REGN (Regeneron Pharmaceuticals) Price-to-Tangible-Book : 2.15 (As of Jul. 22, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Price-to-Tangible-Book?

As of today (2025-07-22), Regeneron Pharmaceuticals's share price is $560.93. Regeneron Pharmaceuticals's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was $260.78. Hence, Regeneron Pharmaceuticals's Price to Tangible Book Ratio of today is 2.15.

The historical rank and industry rank for Regeneron Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.09   Med: 4.4   Max: 15.84
Current: 2.15

During the past 13 years, Regeneron Pharmaceuticals's highest Price to Tangible Book Ratio was 15.84. The lowest was 2.09. And the median was 4.40.

REGN's Price-to-Tangible-Book is ranked better than
65.41% of 1194 companies
in the Biotechnology industry
Industry Median: 3.12 vs REGN: 2.15

A closely related ratio is called PB Ratio. As of today, Regeneron Pharmaceuticals's share price is $560.93. Regeneron Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2025 was $271.56. Hence, Regeneron Pharmaceuticals's P/B Ratio of today is 2.07.


Regeneron Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Regeneron Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Price-to-Tangible-Book Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.69 3.66 3.64 3.85 2.77

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 4.27 4.10 2.77 2.43

Competitive Comparison of Regeneron Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Tangible-Book falls into.


;
;

Regeneron Pharmaceuticals Price-to-Tangible-Book Calculation

Regeneron Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2025 )
=560.93/260.778
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Regeneron Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Executives
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph J Larosa officer: SVP Gen Counsel & Secretary 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Michael S Brown director
Leonard S Schleifer director, officer: President & CEO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George L Sing director LANCET CAPITAL, 45 ROCKEFELLER PLAZA STE 2008, NEW YORK NY 10111
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591